Search results for "hepatitis"

showing 10 items of 1578 documents

Hepatic benefits of HCV cure

2020

Direct-acting antiviral (DAA)-induced HCV clearance conceivably leads to improved outcomes at all stages of liver disease. However, available data suggest that the maximum measurable benefit is obtained by treating patients before they reach the stage of compensated advanced chronic liver disease (cACLD). Ideally, all patients with chronic hepatitis C should be treated before they develop advanced fibrosis or cirrhosis, since even if sustained virologic response (SVR) reduces the risk of hepatic events (e.g. decompensation and hepatocellular carcinoma [HCC]) and improves survival, further progression of liver disease and adverse outcomes, including hepatic deaths, cannot be entirely avoided…

0301 basic medicinemedicine.medical_specialtyCirrhosisHepatocellular carcinomaPortal venous pressureSurvival.Chronic liver diseaseGastroenterology03 medical and health sciencesLiver disease0302 clinical medicineInternal medicinemedicineDecompensationCirrhosiHepatologybusiness.industryHepatitis Cmedicine.diseaseHepatitis Cdigestive system diseases030104 developmental biologyHepatocellular carcinomaPortal hypertension030211 gastroenterology & hepatologybusiness
researchProduct

Antiviral therapy in the palliative setting of HCC (BCLC-B and -C)

2020

The potential impact of direct-acting antivirals (DAAs) in patients with Barcelona Clinic Liver Cancer (BCLC)-B/C stage hepatocellular carcinoma (HCC) is understudied. Patients with HCC have been systematically excluded from randomised controlled trials evaluating the effectiveness of DAAs. Thus, the benefits of DAAs in patients with HCC are less well defined. The presence of active HCC before the initiation of DAA treatment is reported to be a predictor of DAA failure, and studies in patients without HCC have demonstrated that improvements in cirrhosis complications were lower or absent after DAA failure. Even if viral eradication is achieved using DAAs, reversal of liver function impairme…

0301 basic medicinemedicine.medical_specialtyCirrhosisrecurrenceCarcinoma Hepatocellularmedicine.medical_treatmentDecision MakingLiver transplantationAntiviral AgentsRisk Assessment03 medical and health sciences0302 clinical medicineMedicineHumansStage (cooking)HCCIntensive care medicineDAANeoplasm StagingAntiviral Agent...Hepatologybusiness.industryLiver NeoplasmsPalliative CareCancerHepatitis C Chronicmedicine.diseaseBCLC Stage030104 developmental biologyBCLC-Dliver functionHepatocellular carcinoma030211 gastroenterology & hepatologyLiver functionbusinessLiver cancerBCLC-BBCLC-CHuman
researchProduct

Field performance of HBsAg rapid diagnostic tests in rural Ethiopia.

2020

Abstract Point-of-care rapid diagnostic tests (POC-RDTs) are widely used to screen and diagnose hepatitis B virus (HBV) infection and are often the only available diagnostic tools in resource-limited settings. The aim of this study was to evaluate the validity of three hepatitis B surface antigen (HBsAg) POC-RDTs (Healgen®, Advanced Quality™ and Determine™) in an area with high prevalence of HBV in eastern Ethiopia. Results were compared with a commercial enzyme linked immunosorbent assay (ELISA) as gold standard. Quantification of HBsAg was performed in false negative samples. A total of 511 subjects were screened, of whom 81 (15.9 %) were HBsAg-positive with the gold standard. All three P…

0301 basic medicinemedicine.medical_specialtyHBsAgHepatitis B virusPoint-of-care testing030106 microbiologyBiologymedicine.disease_causeDiagnostic toolsGastroenterologySensitivity and Specificity03 medical and health sciencesVirologyInternal medicineparasitic diseasesmedicineHumansVDP::Medisinske Fag: 700Hepatitis B virusHepatitis B Surface AntigensDiagnostic Tests RoutineDiagnostic testGold standard (test)Hepatitis BConfidence intervalRural ethiopia030104 developmental biologyEthiopiaJournal of virological methods
researchProduct

Vaccination and Vaccine Effectiveness: A Commentary of Special Issue Editors

2020

The Special Issue “Vaccination and Vaccine Effectiveness”, published in the journal Vaccines, has the main aim to increase international literature data on vaccine effectiveness and safety and on vaccination strategies in order to reduce vaccine hesitancy and improve vaccination coverage rates. The main topics included in the call for papers were vaccines administered to infants, adolescents, adults, elderly people, at-risk populations (due to comorbidities and personal risk factors) and healthcare workers and strategies adopted to promote vaccination adherence among these categories. This Special Issue started from the assumption that, despite vaccination being universally recognized as on…

0301 basic medicinemedicine.medical_specialtyImmunologyPopulationlcsh:MedicineRubella and varicella vaccinationVaccines AdministeredMeasles03 medical and health sciences0302 clinical medicineQuality of life (healthcare)Internationally adopted childrenDrug DiscoveryHealth caremedicinemeaslesElderly peoplePharmacology (medical)Research article030212 general & internal medicinehepatitis B vaccinationeducationPharmacologyHuman papillomavirus vaccinationeducation.field_of_studyvaccine effectivenesshealthcare workersbusiness.industrylcsh:Rvaccinationmedicine.diseaseinfluenza vaccinationVaccinationEditorial030104 developmental biologyInfectious DiseasesFamily medicineHealthcare workervaccine hesitancymumpsHerpes zoster vaccinationbusinessVaccines
researchProduct

NUPR1 protects liver from lipotoxic injury by improving the endoplasmic reticulum stress response

2021

AbstractBackground and AimsNon-alcoholic fatty liver disease and related hepatic syndromes affect up to one third of the adult population. The molecular mechanisms underlying NAFL etiology remain elusive. Nuclear Protein 1 (NUPR1) expression increases upon cell injury in all organs and recently we report its active participation in the activation of the Unfolded Protein Response (UPR). The UPR typically maintains protein homeostasis, but downstream mediators of the pathway regulate metabolic functions, including lipid metabolism. NUPR1 and UPR increase have been reported in obesity and liver pathologies and the goal of this study was to investigate the roles of NUPR1 in this context.Methods…

0301 basic medicinemedicine.medical_specialtySettore MED/09 - Medicina InternaPPAR-a signalling UPRPeroxisome proliferator-activated receptorContext (language use)UPRDiet High-FatBiochemistry03 medical and health sciencesLiver diseaseMice0302 clinical medicineInternal medicineCell Line TumorGeneticsmedicineBasic Helix-Loop-Helix Transcription FactorsAnimalsHomeostasisHumansMolecular Biologychemistry.chemical_classificationbusiness.industryEndoplasmic reticulumFatty liverNASHLipid metabolismlipotoxicitymedicine.diseaseEndoplasmic Reticulum StressLipid MetabolismNeoplasm Proteins030104 developmental biologyEndocrinologychemistryLipotoxicityLiverNAFLKnockout mouseUnfolded protein responseUnfolded Protein ResponsePPAR-a signallingSteatosisSteatohepatitisbusiness030217 neurology & neurosurgeryNUPR1Biotechnology
researchProduct

Association of Non-Invasive Markers of Liver Fibrosis with HCV Coinfection and Antiretroviral Therapy in Patients with HIV

2019

Abstract The aim of this study was to assess the main effects and interaction between viral hepatitis C (HCV) coinfection and antiretroviral therapy (ART) by using a nonparametric ANOVA on direct and indirect markers of liver fibrosis in HIV-infected patients. The sample included 178 HIV patients aged from 23 to 65 (36% females). The following parameters were determined in blood of patients: hyaluronic acid, pro-matrix metalloproteinase-1, alanine aminotransferase, aspartate aminotransferase, and platelet count. The FIB-4 index was also calculated. The nonparametric ANOVA revealed no significant interaction between HCV coinfection and ART. This provides evidence for an independent contribut…

0301 basic medicinemedicine.medical_specialtyfib-4Liver fibrosisScienceHuman immunodeficiency virus (HIV)medicine.disease_causeGastroenterologypro-mmp-103 medical and health sciences0302 clinical medicineInternal medicinehyaluronic acidmedicinePlateletliver fibrosisMultidisciplinaryaltNon invasiveQmedicine.disease030112 virologyAntiretroviral therapyCoinfection030211 gastroenterology & hepatologyAnalysis of variancenonparametric anovaViral hepatitisastProceedings of the Latvian Academy of Sciences. Section B, Natural Sciences
researchProduct

Frequent NS5A and multiclass resistance in almost all HCV genotypes at DAA failures: What are the chances for second-line regimens?

2017

0301 basic medicinemedicine.medical_specialtyhepacivirusHCV RASTreatment outcomeDrug ResistanceHCV genotypesDrug resistanceBiologyNS5A03 medical and health sciences0302 clinical medicineSecond linedrug resistance viral; humans; retreatment; treatment outcome; antiviral agents; hepacivirus; hepatitis c chronicInternal medicineDrug Resistance Viral; Humans; Retreatment; Treatment Outcome; Antiviral Agents; Hepacivirus; Hepatitis C ChronicDrug Resistance Viralantiviral agentsmedicineViralChronicNS5AhumansHepatologyhepatitis c chronicHepatitis CHepatitis C ChronicSettore MED/07 - Microbiologia e Microbiologia Clinicamedicine.diseaseHepatitis CVirologyHepatology HCV NS5A030104 developmental biologyHCVtreatment outcome030211 gastroenterology & hepatologyretreatmentdrug resistance viral
researchProduct

Beyond the Paradigm of Weight Loss in Non-Alcoholic Fatty Liver Disease: From Pathophysiology to Novel Dietary Approaches

2021

Current treatment recommendations for non-alcoholic fatty liver disease (NAFLD) rely heavily on lifestyle interventions. The Mediterranean diet and physical activity, aiming at weight loss, have shown good results in achieving an improvement of this liver disease. However, concerns related to compliance and food accessibility limit the feasibility of this approach, and data on the long-term effects on liver-related outcomes are lacking. Insulin resistance is a central aspect in the pathophysiology of NAFLD; therefore, interventions aiming at the improvement of insulin sensitivity may be preferable. In this literature review, we provide a comprehensive summary of the available evidence on nu…

0301 basic medicinemedicine.medical_specialtyinsulinlifestyletime-restricted feedingsteatohepatitisDiseaseReviewmetabolic syndrome03 medical and health sciencesLiver disease0302 clinical medicineInsulin resistanceNon-alcoholic Fatty Liver DiseaseWeight lossIntermittent fastingmedicineTime‐restricted feedingHumansTX341-641Intensive care medicineLife StyleNutrition and DieteticsNon‐alcoholicbusiness.industryNutrition. Foods and food supplyintermittent fastinglow-carb dietFatty liverfibrosismedicine.diseaseDietGastrointestinal MicrobiomeLow‐carb diet030104 developmental biologynon-alcoholicFibrosis; Insulin; Intermittent fasting; Lifestyle; Liver disease; Low‐carb diet; Metabolic syndrome; Non‐alcoholic; Steatohepatitis; Time‐restricted feeding; Weight loss030211 gastroenterology & hepatologyInsulin ResistanceSteatohepatitismedicine.symptomMetabolic syndromeweight lossbusinessliver diseaseFood ScienceNutrients
researchProduct

2020

Understanding the importance of the gut microbiota (GM) in non-alcoholic fatty liver disease (NAFLD) has raised the hope for therapeutic microbes. We have shown that high hepatic fat content associated with low abundance of Faecalibacterium prausnitzii in humans and, further, the administration of F. prausnitzii prevented NAFLD in mice. Here, we aimed at targeting F. prausnitzii by prebiotic xylo-oligosaccharides (XOS) to treat NAFLD. First, the effect of XOS on F. prausnitzii growth was assessed in vitro. Then, XOS was supplemented or not with high (HFD, 60% of energy from fat) or low (LFD) fat diet for 12 weeks in Wistar rats (n = 10/group). XOS increased F. prausnitzii growth, having onl…

0301 basic medicinemedicine.medical_specialtymedicine.medical_treatmentFaecalibacterium prausnitziiButyrateGut floradigestive system03 medical and health sciences0302 clinical medicineInternal medicinemedicinechemistry.chemical_classificationNutrition and DieteticsbiologyPrebioticFatty liverfood and beveragesnutritional and metabolic diseasesFatty acidmedicine.diseasebiology.organism_classification3. Good health030104 developmental biologyEndocrinologychemistry030211 gastroenterology & hepatologySteatosisSteatohepatitisFood ScienceNutrients
researchProduct

The Antiviral Properties of Cyclosporine. Focus on Coronavirus, Hepatitis C Virus, Influenza Virus, and Human Immunodeficiency Virus Infections

2020

This review updates current knowledge regarding the risk of viral infections, including COVID-19, in patients treated with cyclosporine. We also shortly refer to bacterial infections and parasitic infestations in patients treated with cyclosporin. Cyclosporine is an immunosuppressive drug, which is widely used in medicine, including in the treatment of autoimmune skin diseases in dermatology, rheumatology, ophthalmology and nephrology, and in organ transplantation. A usual concern associated with immunosuppressive treatment is the potential risk of infections. Interestingly, several data indicate a relatively low risk of infections, especially viral infections, in patients receiving cyclosp…

0301 basic medicinemedicine.medical_specialtyvirusesmedicine.medical_treatmentHepatitis C viruscoronavirusReviewBiologymedicine.disease_causeGeneral Biochemistry Genetics and Molecular BiologyVirusOrgan transplantation030207 dermatology & venereal diseases03 medical and health sciences0302 clinical medicineRotavirusmedicinecyclosporineinfectionstacrolimuslcsh:QH301-705.5Coronavirushuman papilloma virus infectionGeneral Immunology and MicrobiologyHepatitis Cmedicine.diseasecalcineurin inhibitorshuman herpesvirusVirologyTacrolimusAIDShepatitis flu030104 developmental biologyImmunosuppressive druglcsh:Biology (General)cyclophilinGeneral Agricultural and Biological SciencesBiology
researchProduct